Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART

Summary

This is an open-label, prospective, randomized, controlled study of the safety and efficacy including clinical, immunologic, and virologic assessments of adding Ampligen to "HAART" in HIV infected patients with CD4 counts \>300 and HIV-1 plasma RNA \>500 and \<30,000 copies/ml (PCR).

Timeline

Start

2001-05

Primary completion

2005-09

Completion

2005-09

Drugs

Indications